Mass Balance Study of MT-1303
Primary Purpose
Relapsing-remitting Multiple Sclerosis
Status
Completed
Phase
Phase 1
Locations
United Kingdom
Study Type
Interventional
Intervention
MT-1303
Sponsored by
About this trial
This is an interventional treatment trial for Relapsing-remitting Multiple Sclerosis
Eligibility Criteria
Inclusion Criteria:
- Caucasian male aged 30 to 65 at Screening.
- Body weight of ≥60 kg, and a BMI ranging from 18.0 to 32.0 kg/m2 at Screening and Day -1.
- Normal or not clinically significant ECG as defined by a HR between 50 and 100 bpm inclusive at Screening, Day -1 and pre-dose.
- Vital signs within the following ranges at Screening and Day -1,Body temperature: 35.0 to 37.5 °C,SBP: 90 to 140 mmHg,DBP: 50 to 90 mmHg.
- Regular daily bowel movements.
Exclusion Criteria:
- Radiation exposure, including that from the present study, excluding background radiation but including diagnostic x-rays and other medical exposures, exceeding 5 mSv in the last 12 months or 10 mSv in the last 5 years. No occupationally exposed worker, as defined in the Ionising Radiation Regulations 1999, shall participate in the study.
- Previous medical history of tuberculosis, or in the opinion of the Investigator, a recurrent medical history of cold sores, pharyngitis, urinary tract infection, diarrhoea/dysentery, chest infections or fungal infections.
Any surgical or medical condition which might significantly alter the absorption, distribution, metabolism or excretion of drugs or which may jeopardise the subject in case or participation in the study. The investigator should be guided by evidence of any of the following:
- history of inflammatory bowel syndrome,gastritis, ulcers, gastrointestinal or rectal bleeding;
- history of major gastrointestinal tract surgery such as gastrectomy, gastroenterostomy, or bowel resection
Sites / Locations
- Investigational site
Arms of the Study
Arm 1
Arm Type
Experimental
Arm Label
MT-1303
Arm Description
[14C] MT-1303 after a single oral dose
Outcomes
Primary Outcome Measures
Total radioactivity in urine and faeces
Secondary Outcome Measures
PK of total radioactivity in plasma
Full Information
NCT ID
NCT02293967
First Posted
November 14, 2014
Last Updated
March 13, 2015
Sponsor
Mitsubishi Tanabe Pharma Corporation
1. Study Identification
Unique Protocol Identification Number
NCT02293967
Brief Title
Mass Balance Study of MT-1303
Official Title
An Open-label, Mass Balance Study to Investigate the Absorption, Metabolism and Excretion of [14C] MT-1303 After a Single Oral Dose to Healthy Male Subjects.
Study Type
Interventional
2. Study Status
Record Verification Date
March 2015
Overall Recruitment Status
Completed
Study Start Date
September 2014 (undefined)
Primary Completion Date
December 2014 (Actual)
Study Completion Date
December 2014 (Actual)
3. Sponsor/Collaborators
Responsible Party, by Official Title
Sponsor
Name of the Sponsor
Mitsubishi Tanabe Pharma Corporation
4. Oversight
5. Study Description
Brief Summary
The purpose of this study is to investigate the absorption, metabolism and excretion of MT-1303 in healthy subjects.
6. Conditions and Keywords
Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Relapsing-remitting Multiple Sclerosis
7. Study Design
Primary Purpose
Treatment
Study Phase
Phase 1
Interventional Study Model
Single Group Assignment
Masking
None (Open Label)
Allocation
N/A
Enrollment
8 (Actual)
8. Arms, Groups, and Interventions
Arm Title
MT-1303
Arm Type
Experimental
Arm Description
[14C] MT-1303 after a single oral dose
Intervention Type
Drug
Intervention Name(s)
MT-1303
Primary Outcome Measure Information:
Title
Total radioactivity in urine and faeces
Time Frame
up to 10 weeks
Secondary Outcome Measure Information:
Title
PK of total radioactivity in plasma
Time Frame
up to 10 weeks
10. Eligibility
Sex
Male
Minimum Age & Unit of Time
30 Years
Maximum Age & Unit of Time
65 Years
Accepts Healthy Volunteers
Accepts Healthy Volunteers
Eligibility Criteria
Inclusion Criteria:
Caucasian male aged 30 to 65 at Screening.
Body weight of ≥60 kg, and a BMI ranging from 18.0 to 32.0 kg/m2 at Screening and Day -1.
Normal or not clinically significant ECG as defined by a HR between 50 and 100 bpm inclusive at Screening, Day -1 and pre-dose.
Vital signs within the following ranges at Screening and Day -1,Body temperature: 35.0 to 37.5 °C,SBP: 90 to 140 mmHg,DBP: 50 to 90 mmHg.
Regular daily bowel movements.
Exclusion Criteria:
Radiation exposure, including that from the present study, excluding background radiation but including diagnostic x-rays and other medical exposures, exceeding 5 mSv in the last 12 months or 10 mSv in the last 5 years. No occupationally exposed worker, as defined in the Ionising Radiation Regulations 1999, shall participate in the study.
Previous medical history of tuberculosis, or in the opinion of the Investigator, a recurrent medical history of cold sores, pharyngitis, urinary tract infection, diarrhoea/dysentery, chest infections or fungal infections.
Any surgical or medical condition which might significantly alter the absorption, distribution, metabolism or excretion of drugs or which may jeopardise the subject in case or participation in the study. The investigator should be guided by evidence of any of the following:
history of inflammatory bowel syndrome,gastritis, ulcers, gastrointestinal or rectal bleeding;
history of major gastrointestinal tract surgery such as gastrectomy, gastroenterostomy, or bowel resection
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
Pui Leung
Organizational Affiliation
Quotient Clinical
Official's Role
Principal Investigator
Facility Information:
Facility Name
Investigational site
City
Ruddington
State/Province
Nottingham
Country
United Kingdom
12. IPD Sharing Statement
Citations:
PubMed Identifier
30231665
Citation
Kifuji T, Inoue S, Furukawa M, Perez Madera B, Goto T, Kumagai H, Mair SJ, Kawaguchi A. Absorption, disposition and metabolic pathway of amiselimod (MT-1303) in healthy volunteers in a mass balance study. Xenobiotica. 2019 Sep;49(9):1033-1043. doi: 10.1080/00498254.2018.1525508. Epub 2018 Dec 21.
Results Reference
derived
Learn more about this trial
Mass Balance Study of MT-1303
We'll reach out to this number within 24 hrs